PhotoPharmics is a clinical-stage medical device company developing next-generation treatments for neurodegenerative disorders through the eyes.
Location: United States, Utah, American Fork
Employees: 1-10
Phone: +1 801-770-6960
Total raised: $6M
Founded date: 2011
Investors 3
| Date | Name | Website |
| - | Angel Star... | angelstarv... |
| - | Salt Lake ... | sllsa.com |
| - | Kickstart | kickstartf... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 21.04.2025 | Series B | $6M | - |
Mentions in press and media 18
| Date | Title | Description |
| 15.05.2026 | PhotoPharmics Completes Pivotal, Phase 3, Light for PD Clinical Trial; to Present Topline Data at World PD Congress | Completion of 351-patient trial marks key milestone for the Celeste® investigational photo-neuromodulation program; topline data presented May 26 in Phoenix This milestone belongs first to the patients — people living with Parkinson's disea... |
| 16.04.2026 | PhotoPharmics to Participate in AAN Annual Meeting as Phase 3 Light for PD Trial Nears Completion | Company available for scientific exchange as pivotal study approaches completion. Data Readout Anticipated at World Parkinson Congress. AAN convenes the clinicians and researchers who are shaping the future of Parkinson's care.” — Kent Sava... |
| 28.08.2025 | PhotoPharmics Forms Commercial Advisory Board to Guide Market Launch of Breakthrough Parkinson’s Therapy | Renowned leaders in neurology, movement disorders, and commercialization join to shape Celeste® market strategy This board brings unmatched expertise to help us navigate pricing, access, and adoption strategies that will get Celeste to the ... |
| 21.05.2025 | PhotoPharmics Strengthens Executive Team with Appointments of Samantha John and Greg Schneider | Veteran leaders join to accelerate commercialization and market access strategy as company advances toward regulatory submission and market launch We’ve assembled a world-class team that’s uniquely suited to the opportunity ahead.” — Kent S... |
| 22.04.2025 | Illuminating Hope: PhotoPharmics' Breakthrough in Parkinson’s Treatment | In the world of medical innovation, light can be a beacon of hope. PhotoPharmics, a trailblazer in specialized light therapy, has just secured a significant $6 million in funding. This investment is not just a financial boost; it’s a lifeli... |
| 21.04.2025 | PhotoPharmics Secures $6M for Parkinson’s Light Therapy Trial | What You Should Know: – PhotoPharmics, a leader in specialized light therapy for neurodegenerative diseases, today announced the close of its oversubscribed $6 million Series B extension. – The round was led by Kickstart Fund with participa... |
| 18.04.2025 | PhotoPharmics Closes Oversubscribed $6 Million Series B Extension to Advance FDA Breakthrough Parkinson’s Device | Funding supports key milestones as the Pivotal, Phase 3 trial surpasses 200 enrolled participants This funding gives us the runway we need to complete our FDA research, build strategic partnerships, and ensure the best possible outcomes for... |
| 08.04.2025 | PhotoPharmics Reaches 200 Participants in Landmark Light for PD Clinical Trial | Two-thirds enrolled in one of the largest remote Parkinson’s trials—redefining access and inclusion in therapeutic research There’s a large segment of the Parkinson’s community that is still struggling with persistent motor and non-motor sy... |
| 07.02.2025 | PhotoPharmics Achieves 50% Enrollment in Pioneering Phase 3 Parkinson’s Trial | Advancing Light Therapy Research to Enhance Quality of Life for Parkinson’s Patients This trial is important because it addresses the often-overlooked aspects of Parkinson’s disease—non-motor symptoms that severely impact daily life but hav... |
| 31.01.2025 | PhotoPharmics Announces Leadership Transition in Clinical & Scientific Advisory Board | Dr. Hauser’s dedication to patient-centered care and his expertise in advancing scientific discovery make him uniquely qualified to guide us through this next chapter.” — Kent Savage, CEO LEHI, UT, UNITED STATES, January 31, 2025 /EINPressw... |
Show more